CURRENT AND EMERGING PHARMACOTHERAPY FOR DYSLIPIDEMIA: A COMPREHENSIVE STUDY
Dyslipidemia is a primary driver of atherosclerotic cardiovascular disease. While statins reduce LDL-C and cardiovascular events, statin intolerance and failure to achieve guideline targets limit their utility. To review the mechanism, efficacy, safety, and clinical positioning of current and emerging antihyperlipidemi...